 Connection
Timothy McKinsey to Heart Diseases
This is a "connection" page, showing publications Timothy McKinsey has written about Heart Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.833 |
|
|
|
-
Schuetze KB, Koch KA, McKinsey TA. The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases. Future Med Chem. 2016 09; 8(13):1533-6.
Score: 0.419
-
Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp. 2006; 274:3-12; discussion 13-9, 152-5, 272-6.
Score: 0.200
-
Alexanian M, Przytycki PF, Micheletti R, Padmanabhan A, Ye L, Travers JG, Gonzalez-Teran B, Silva AC, Duan Q, Ranade SS, Felix F, Linares-Saldana R, Li L, Lee CY, Sadagopan N, Pelonero A, Huang Y, Andreoletti G, Jain R, McKinsey TA, Rosenfeld MG, Gifford CA, Pollard KS, Haldar SM, Srivastava D. A transcriptional switch governs fibroblast activation in heart disease. Nature. 2021 07; 595(7867):438-443.
Score: 0.146
-
Bush EW, McKinsey TA. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res. 2010 Feb 05; 106(2):272-84.
Score: 0.067
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|